Literature DB >> 16481451

Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review.

Kimberly D Clay1, John S Hanson, Scott D Pope, Richard W Rissmiller, Preston P Purdum, Peter M Banks.   

Abstract

BACKGROUND: Telithromycin is a ketolide antibiotic approved by the U.S. Food and Drug Administration for acute bacterial infections causing sinusitis, bronchitis, and community-acquired pneumonia.
OBJECTIVE: To describe 3 cases of severe hepatotoxicity in patients receiving telithromycin.
DESIGN: Case reports.
SETTING: A tertiary care medical center. PATIENTS: 3 previously healthy patients who had recently taken telithromycin and took no other prescription medications. MEASUREMENTS: Serologic, histologic, and liver function tests.
RESULTS: Within a few days of receiving telithromycin, the patients presented with acute hepatitis. All had jaundice and markedly abnormal results on liver function tests. Results of viral serologic tests were negative. One patient spontaneously recovered, 1 required orthotopic liver transplantation, and 1 died. Histologic examination in the latter 2 patients showed massive hepatic necrosis. LIMITATIONS: Two patients had some history of alcohol use. The frequency of severe telithromycin-related hepatotoxicity cannot be established with case reports.
CONCLUSIONS: Telithromycin can cause severe hepatotoxicity. Caution is advised in prescribing this drug pending additional postmarketing surveillance data.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16481451     DOI: 10.7326/0003-4819-144-6-200503210-00121

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  30 in total

1.  Synthesis and structure-activity relationships of novel lincomycin derivatives. Part 2. Synthesis of 7(S)-7-deoxy-7-(4-morpholinocarbonylphenylthio)lincomycin and its 3-dimensional analysis with rRNA.

Authors:  Yoshinari Wakiyama; Ko Kumura; Eijiro Umemura; Satomi Masaki; Kazutaka Ueda; Takashi Watanabe; Mikio Yamamoto; Yoko Hirai; Keiichi Ajito
Journal:  J Antibiot (Tokyo)       Date:  2015-12-16       Impact factor: 2.649

2.  Hepatic adverse drug reactions: a case/non-case study in Italy.

Authors:  Domenico Motola; Antonio Vargiu; Roberto Leone; Alfredo Cocci; Francesco Salvo; Barbara Ros; Ilaria Meneghelli; Mauro Venegoni; Paola Maria Cutroneo; Alberto Vaccheri; Gianpaolo Velo; Nicola Montanaro
Journal:  Eur J Clin Pharmacol       Date:  2006-11-22       Impact factor: 2.953

3.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors:  Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2007-03-01       Impact factor: 9.079

4.  Leber's hereditary optic neuropathy associated with cocaine, ecstasy and telithromycin consumption.

Authors:  Elena Cardaioli; Paola Da Pozzo; Gian Nicola Gallus; Rossella Franceschini; Alessandra Rufa; Maria Teresa Dotti; Aldo Caporossi; Antonio Federico
Journal:  J Neurol       Date:  2007-03-02       Impact factor: 4.849

5.  Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects.

Authors:  J Gordon Still; Jennifer Schranz; Thorsten P Degenhardt; Drusilla Scott; Prabhavathi Fernandes; Maria J Gutierrez; Kay Clark
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

6.  Synthesis and SARs of novel lincomycin derivatives Part 5: optimization of lincomycin analogs exhibiting potent antibacterial activities by chemical modification at the 6- and 7-positions.

Authors:  Yoshinari Wakiyama; Ko Kumura; Eijiro Umemura; Satomi Masaki; Kazutaka Ueda; Yasuo Sato; Yoko Hirai; Yoshio Hayashi; Keiichi Ajito
Journal:  J Antibiot (Tokyo)       Date:  2017-11-01       Impact factor: 2.649

7.  Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.

Authors:  Allen D Brinker; Jenna Lyndly; Joseph Tonning; David Moeny; Jonathan G Levine; Mark I Avigan
Journal:  Drug Saf       Date:  2013-12       Impact factor: 5.606

8.  Synthesis and structure-activity relationships of novel lincomycin derivatives part 3: discovery of the 4-(pyrimidin-5-yl)phenyl group in synthesis of 7(S)-thiolincomycin analogs.

Authors:  Yoshinari Wakiyama; Ko Kumura; Eijiro Umemura; Satomi Masaki; Kazutaka Ueda; Yasuo Sato; Takashi Watanabe; Yoko Hirai; Keiichi Ajito
Journal:  J Antibiot (Tokyo)       Date:  2016-10-05       Impact factor: 2.649

9.  Synthesis and antibacterial activity of novel lincomycin derivatives. IV. Optimization of an N-6 substituent.

Authors:  Ko Kumura; Yoshinari Wakiyama; Kazutaka Ueda; Eijiro Umemura; Yoko Hirai; Keiko Yamada; Keiichi Ajito
Journal:  J Antibiot (Tokyo)       Date:  2017-11-08       Impact factor: 2.649

Review 10.  The evolving role of chemical synthesis in antibacterial drug discovery.

Authors:  Peter M Wright; Ian B Seiple; Andrew G Myers
Journal:  Angew Chem Int Ed Engl       Date:  2014-07-02       Impact factor: 15.336

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.